Clinical trial for the treatment of COVID-19 with Chloroquine and Colchicine
- Conditions
- Coronavirus disease 2019 (COVID-19)B34.2
- Registration Number
- RBR-8jyhxh
- Lead Sponsor
- Hospital das Clínicas de Ribeirão Preto
- Brief Summary
Patients who received colchicine in this randomised, double-blinded, placebo-controlled clinical trial presented better evolution in terms of the need for supplemental oxygen and the length of hospitalisation. Serum CRP was a laboratory marker of clinical improvement. Colchicine was safe and well tolerated.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Data analysis completed
- Sex
- Not specified
- Target Recruitment
- Not specified
Moderate or severe forms of COVID-19; 18 years or older; body weight of 50 kg or more; serum Ca2+ and K+ normal; QT interval lower than 450 ms at 12 derivations electrocardiogram; beta-HCG (serum or urine) negative (if woman under 50).
Mild and critical forms of COVID-19; allergy to any of the medications under study; diagnosis of porphyria, myasthenia gravis or uncontrolled arrhythmia at admission; pregnancy; use of digoxin, amiodarone, verapamil or metoprolol; use of protease inhibitors; history of chronic liver disease with liver dysfunction; unable to understand the information contained in the Consent Form.
Study & Design
- Study Type
- Intervention
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method